Phase 1 clinical trial of autologous dendritic cells to induce antigen-specific tolerance

自体树突状细胞诱导抗原特异性耐受的一期临床试验

• 批准号: nhmrc : 301244
• 负责人: Dr Paul Kubler
• 金额: $ 11.01万
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2004-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-1-clinical-specific-tolerance/100593
• 关键词: Phase; clinical; trial; autologous; dendritic

We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their disease

我们之前已经在小鼠体内产生了经过修饰的树突状细胞，一旦免疫反应开始，这些细胞就能抑制免疫反应。该项目将开发树突状细胞疫苗作为人类临床使用的平台技术。我们的目标是在I期临床试验中，在一组健康志愿者和一组类风湿关节炎患者中，证明修饰的人类自体树突状细胞抑制对模型抗原的免疫反应的能力